Moderna FY2025 EPS Estimate Decreased by Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Leerink Partnrs cut their FY2025 EPS estimates for Moderna in a report released on Sunday, November 17th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($9.90) per share for the year, down from their prior estimate of ($9.89). The consensus estimate for Moderna’s current full-year earnings is ($9.43) per share.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the firm posted ($1.39) earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis.

Other research analysts also recently issued reports about the company. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday. TD Cowen reduced their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Leerink Partners dropped their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group decreased their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Stock Down 5.6 %

Moderna stock opened at $37.29 on Wednesday. The company has a market capitalization of $14.35 billion, a PE ratio of -6.41 and a beta of 1.69. Moderna has a 12-month low of $35.80 and a 12-month high of $170.47. The firm’s fifty day moving average is $57.82 and its 200 day moving average is $96.07. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its position in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Wellington Management Group LLP grew its stake in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the last quarter. Two Sigma Advisers LP purchased a new position in shares of Moderna in the third quarter worth about $23,825,000. International Assets Investment Management LLC lifted its stake in shares of Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares during the last quarter. Finally, Matrix Capital Management Company LP grew its position in Moderna by 60.8% during the 1st quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock worth $77,789,000 after acquiring an additional 276,000 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 2,930 shares of company stock worth $217,170 in the last three months. 15.20% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.